Allergy is an exaggerated, hypersensitive immune response to innocuous environmental antigens, characterised by inflammation and mediated by immunoglobulin E (IgE) antibodies. Symptoms of allergy depend on the site of allergen contact and range from being uncomfortable (itching, sneezing and breathlessness) to serious (anaphylaxis). The development of allergy is due to environmental and genetic factors; the heritable component is known as atopy, defined as a predisposition to the overproduction of IgE. The prevalence of allergies such as hay fever (seasonal allergic rhinitis), eczema (atopic dermatitis) and asthma are increasing in Westernised societies. Antihistamines are the first‐line drug treatment for allergy; however, these often fail to alleviate all symptoms satisfactorily and are not clinically effective in asthma, illustrating the heterogeneity of allergic disorders. This has necessitated the development of alternative medication for asthma, which targets airway symptoms, for example, β
2
‐adrenergic receptor agonists. New, more effective therapeutic approaches are still required to treat allergic disease.
Key Concepts:
Allergy describes a variety of symptoms, which cause discomfort but can be life threatening.
Allergic symptoms are a defining feature of diseases such as hay fever, eczema, asthma and food allergy.
Atopy is a heritable trait (defined by elevated IgE or positive skin prick test), which predisposes an individual to allergic disease.
Allergies are becoming increasingly common in Westernised societies and represent a significant economic burden, but the reasons for this are not fully understood.
Recent improvements in technology have facilitated studies, which link genetic variants to atopy susceptibility, with confidence.
New therapeutics are needed to more adequately treat symptoms of allergic diseases such as hay fever, eczema and asthma.
Histamine is a key inflammatory mediator, the action of which might be targeted in new ways to treat the symptoms of allergic disease.